This Battlefield 200 startup has developed blood-purification tech to save children

Sepsis claims the lives of millions of children under five annually. To combat this, startup Efferon developed Efferon NEO, a unique blood-purification device designed for infants that simultaneously removes dangerous toxins and cytokines. After receiving European approval in April as the first multi-functional device for pediatric sepsis, it is now used in intensive care units across 30 countries, with plans to seek FDA approval next.

Efferon, çocuklarda sepsise bağlı organ yetmezliği riskini azaltmayı amaçlayan Efferon NEO cihazını 30 ülkede kullanıma sundu. Şirket, ABD onayı için hazırlanıyor.

This Battlefield 200 startup has developed blood-purification tech to save children

This Battlefield 200 startup has developed blood-purification tech to save children — per TechCrunch

This Battlefield 200 startup has developed blood-purification tech to save children

This Battlefield 200 startup has developed blood-purification tech to save children

Curate Feeds | Make Collections | Customize Email Briefs

The Austrian medtech is using multimodal blood purification to tackle sepsis and septic shock, with devices for adult and pediatric intensive care.

Every minute one person in Europe dies from sepsis or septic shock. Sepsis arises when the body’s response to an infection injures its own tissues and organs. It may lead to shock, multi-organ failure...

Every minute one person in Europe dies from sepsis or septic shock. Sepsis arises when the body’s response to an infection injures its own tissues and organs. It may lead to shock, multi-organ failure, and death – especially if not recognised early and treated promptly. Sepsis is the final common pathway to death from most infectious diseases worldwide, including viral infections such as SARS-CoV-2 / COVID-19. In 2021, there were an estimated 166 million cases of sepsis worldwide, resulting in 21.4 million deaths — nearly one-third of all global deaths. One company looking to address this challenge is Austria-based Efferon, which is developing technology designed to intervene in the inflammatory response that can make sepsis so difficult to treat. Founded in 2016, its blood-purification devices work alongside existing treatments, removing bacterial toxins and excessive inflammatory molecules from the bloodstream to stabilise critically ill patients with sepsis and septic shock. “We are selling time” Time is critical in sepsis diagnosis and treatment: patients can deteriorate rapidly, while the inflammatory response can continue even after treatment of the underlying infection has begun. Antibiotics and standard therapies have to be used as the first line of defence. Current sepsis care largely focuses on...

Biotechcompany Efferon has raised €2.5 million in a seed funding round led by privateinvestors from the DACH region to support the European commercial expansion ofEfferon LPS, its hemoadsorption devic...

Efferon is a biotech company developing hemoadsorption devices designed to remove endotoxins and inflammatory mediators from the bloodstream for the treatment of sepsis, septic shock and other inflammation-related...